A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
N.V. Rajeshkumar(Johns Hopkins University), Manuel Hidalgo(Spanish National Cancer Research Centre)
Cited by 88
Related Papers
An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
|Clinical Cancer Research|2006|412
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
|British Journal of Cancer|2013|291
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
|Molecular Cancer Therapeutics|2010|246
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway
|Annals of Oncology|2004|176
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
|British Journal of Cancer|2007|83